News blog
FDA chemist charged with insider trading
Few are better placed to beat the market – illegally – than employees intimately involved with new drug marketing approvals at the US Food and Drug Administration (FDA). The temptation was apparently too much for Cheng Yi Liang, a 57-year-old chemist in FDA’s Center for Drug Evaluation and Research (CDER), the agency power center that approves new drugs (building at right).
Recent comments on this blog
Experiments reveal that crabs and lobsters feel pain
US research ethics agency upholds decision on informed consent
Chemistry credit disputes under the spotlight
Chemistry credit disputes under the spotlight
Contamination created controversial ‘acid-induced’ stem cells